



## Press release

### **STADA wins 2018 Global Generics & Biosimilars Award in “Company of the Year, EMEA” category**

Bad Vilbel, October 11, 2018 – STADA Arzneimittel AG fared well at this year's Global Generics & Biosimilars Awards and was named "Company of the Year, EMEA (Europe, Middle East, and Africa)" by an independent jury. The award ceremony of international trade magazine Generics Bulletin took place on Tuesday evening at the Palacio Municipal de Congresos in Madrid, Spain. STADA won this award for its successful strategy based on OTC products, generics, and specialty pharmaceuticals including biosimilars after being taken over by financial investors Bain Capital and Cinven.

Most importantly, STADA was recognized for implementing strategic acquisitions and cooperations in branded products and biosimilars in less than one year, which has decisively contributed to the expansion and internationalization of its product portfolio. This was also accompanied by a noticeable change in the corporate culture at STADA from decentralized sales companies to increased international exchange among employees. To this end, STADA introduced new internal communications tools and encouraged employees worldwide to create more synergies and share knowledge. "I am really pleased to receive this award on behalf of our more than 10,000 employees. Many teams have successfully worked on our growth strategy in recent months and we are seeing good results. This is an excellent foundation on which we will continue to build," emphasizes STADA Chief Executive Officer Peter Goldschmidt.

The Global Generics & Biosimilars Awards were presented for the fifth time in a row by leading trade magazine Generics Bulletin, the in cooperation with IQVIA.

#### **About STADA Arzneimittel AG**

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2017,

Executive Board: Peter Goldschmidt (CEO) / Mark Keatley / Miguel Pagan Fernandez  
Supervisory Board Chairman: Dr. Günter von Au



STADA achieved adjusted Group sales of Euro 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 433.9 million and adjusted net income of Euro 195.6 million. As of December 31, 2017, STADA employed 10,176 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastrasse 2–18 / 61118 Bad Vilbel – Germany /

Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: [press@stada.de](mailto:press@stada.de)

Or visit us on the Internet at [www.stada.com/press](http://www.stada.com/press)

Additional information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2–18 / 61118 Bad Vilbel – Germany /

Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: [ir@stada.de](mailto:ir@stada.de)

Or visit us on the Internet at [www.stada.com/investor-relations](http://www.stada.com/investor-relations)

Executive Board: Peter Goldschmidt (CEO) / Mark Keatley / Miguel Pagan Fernandez

Supervisory Board Chairman: Dr. Günter von Au